Background-Langerhans cells (LCs) are self-renewing epidermal myeloid cells that can migrate and mature into dendritic cells. Recipient LCs that survive cytotoxic therapy given in preparation for allogeneic hematopoietic cell transplantation may prime donor T cells to mediate cutaneous graft-versus-host disease (GVHD). This possible association, however, has not been investigated in the setting of nonmyeloablative allografting.
INTRODUCTION
Langerhans cells (LCs) are myeloid dendritic cells (DCs) of the epidermis that have local self-renewal capacity in mice (1,2) and humans (3, 4) . Persistent recipient LCs were originally proposed to cause graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (allo-HCT) with myeloablative (MA) conditioning in humans (5, 6) . Murine models of allo-HCT have confirmed that recipient LCs can persist for prolonged periods after cytotoxic conditioning therapy (1, 2) and are sufficient to induce cutaneous GVHD in recipients of MHC-mismatched (2) and MHC-matched grafts (7) . In mixed chimeras receiving donor-lymphocyte infusion, LCs promote GVHD by licensing donor CD8+ T cells infiltrating inflamed skin (8) . In these models, inflammation also plays a key role in depleting recipient LCs and attracting monocyte-derived cells to form new donor-derived LCs in the epidermis (9) .
Human studies of allo-HCT with reduced-intensity conditioning regimens, compared to those with MA conditioning regimens, have demonstrated that the survival of recipient LCs is significantly prolonged and that full donor engraftment of LCs is associated with GVHD (10) . However, the ability of recipient LCs to proliferate and survive has not been explored after nonmyeloablative (NA) allo-HCT with fludarabine and low-dose (2-3 Gy) TBI conditioning, in which acute GHVD has been shown to be significantly delayed (11) . Furthermore, the relationship between cutaneous inflammation and engraftment of donor LCs has not been explored at the histological level.
In this study, we therefore examined LC homeostasis in relation to hematopoietic cell chimerism, clinical and histopathological GVHD, and skin inflammation after NA or MA allo-HCT. Our results show that recipient LCs proliferate in situ and persist for prolonged periods after NA conditioning. Repopulation with donor LCs occurs in association with cutaneous inflammation but does not correlate with histopathological skin GVHD or clinical diagnosis of GVHD.
RESULTS
Forty-eight patients who had biopsies at one or more of 3 time-points after sex-mismatched allo-HCT were included in the analysis (day 28, n=40; day 56, n=12; day 84, n=22). Twenty-three patients had received NA conditioning, and 25 had received MA conditioning (Table 1) . Since Langerin is a stable antigen that resists heat denaturation and proteolytic treatment, simultaneous XY-FISH and post-hybridization immunofluorescence staining could be performed to visualize LC homeostasis in situ (Fig 1A-B) . A first round of staining for Langerin and Ki-67 followed by antibody stripping and secondary FISH/ immunofluorescence demonstrated that persisting host LCs were proliferating (Fig 1C) . Donor epidermal LC chimerism was significantly lower after NA conditioning compared with MA conditioning (day 28: 7% vs. 95%, p=0.001; day 56: 34% vs. 100%, p=0.05; day 84: 94% vs. 97%, p=0.48) (Fig 2A) . Donor LC chimerism after NA conditioning (Fig 2A) was also significantly lower than the donor DC chimerism in peripheral blood or bone marrow (day 28: 7% vs. 100%, p=0.001; day 56: 34% vs. 100%; p=0.05) (Fig 2B-C) or the total CD33 + myeloid compartment of blood (Fig 2D) . CD3 + T cells in the blood also showed lower chimerism after NA conditioning compared with MA conditioning (day 28: 78% vs. 100; p=0.02) (Fig 2E) , in keeping with the delayed onset of GVHD after NA conditioning (11) . Based on presence or absence of acute GVHD (≥ grade 2) at day 28, median CD3 cell chimerism was 78% among recipients without GVHD (n=17), and 100% among those with GVHD (n=7) (p=0.07).
Although persistence of host LCs after allo-HCT has been implicated in GVHD, we did not find a correlation between the highly variable degrees of LC chimerism on day 28 after NA conditioning and clinical or histopathological acute and chronic skin GVHD. Levels of day-28 LC-chimerism (<50% vs >50%) were not significantly associated with clinical skin stage 2-4 acute GVHD (45% vs 44%, p=0.95), histo-pathological stage 1-4 acute skin GVHD (43% vs 67%, p=0.14), or the rate of chronic GVHD meeting NIH criteria (32% vs 45% at 2 years, HR=1.2, p=0.77). Among patients with chronic GVHD, the types of chronic skin GVHD were similar between groups defined by day-28 LC chimerism. Day-28 LCchimerism was also not associated with presence or absence of acute GVHD at this time (data not shown).
Since clinical GVHD reflects a late effector response and is likely to play a role in promoting donor LC engraftment, we also examined skin biopsies for early inflammatory changes (dermal cell infiltration and epidermal thickening) that were not classified as skin GVHD by our pathologist. We found that increased skin inflammation scores were strongly associated with earlier donor LC chimerism (p=0.009; Fig 2F) .
DISCUSSION
These results show that recipient LCs proliferate in situ after allo-HCT and that, compared with MA conditioning, minimally toxic transplant NA conditioning consisting of low-dose TBI (2-3 Gy) and fludarabine is associated with a two-month delay in donor LCengraftment. Direct histological analysis is consistent with the findings in mice that inflammation is required to attract donor-derived LC-precursors to the epidermis.
Delayed LC-engraftment was reported after conditioning with a reduced-intensity regimen of fludarabine (150 mg/m 2 ) and melphalan (140mg/m 2 ) compared with conventional highdose regimens (10) . With the NA conditioning regimen examined in the present study, we observed an even greater delay in donor LC-engraftment, resulting in only 7% donor signal at day 28 and 34% at day 56, compared with 37% on day 40 that was previously reported after reduced-intensity conditioning. In contrast, the kinetics of donor engraftment of peripheral blood and bone marrow DCs was rapid and independent of conditioning intensity, in keeping with previous reports (10, 12, 13) . Unlike previous reports we were able to measure LC-chimerism in situ thus avoiding potential bias introduced by the isolation of LCs through in vitro culture (10, 13) .
The role of LCs in GVHD remains controversial. Although some studies have shown that UVB-irradiation during allo-HCT decreases the risk of acute skin GVHD, the findings were based on relatively small sample sizes and may also be explained by mechanisms unrelated to UVB-mediated depletion of LCs (14) . Targeted depletion of host LCs in animal models of allo-HCT does not protect from GVHD, presumably because other host DCs are able to prime allo-reactive donor T cells (15) . LCs are sufficient to induce cutaneous GVHD, however, when they are the only remaining host antigen-presenting cell in recipients of MHC-mismatched (2) and MHC-matched grafts (7), and when mismatched donor lymphocytes and a local inflammatory stimulus are given to mixed chimeras (8) . Complete loss of DCs but preservation of LCs and macrophages occurs in humans with DC, monocyte, B and NK lymphoid (DCML) deficiency / monocytopenia with Mycobacterium avium complex (monoMAC) due to GATA2-mutation. A potential role of LCs in human GVHD is suggested by the observation that these patients still experience GVHD when given hematopoietic allografts, although the contribution of macrophages and other nonprofessional antigen-presenting cells to donor T cell activation cannot be excluded (16, 17) .
Although the presence of skin inflammation correlated with donor LC-engraftment in our study, many potential explanations can account for the lack of relationship between histological or clinical GVHD and LC-chimerism. First, recipient LCs constitute an afferent pathway of donor T cell activation, while GVHD is a temporally separated effector phenomenon. Second, although persistent recipient LCs may promote GVHD, skin inflammation rapidly mobilizes them (18) increasing the proportion of donor LCs in animal models (2) . Thus recipient LCs are more likely to survive in the absence of GVHD. Finally, the overall grading of clinical GVHD is retrospective and, hence, not easily recorded as a time-dependent variable. For these reasons, clinically useful predictions of GVHD are unlikely to be derived from the measurement of LC-chimerism.
PATIENTS AND METHODS

Patients
From November 2006 to February 2009, punch biopsies were obtained from the skin at the posterior iliac crest of recipients who had routine marrow biopsies under local anesthesia prospectively on days 28, 56 and 84 days after allo-HCT for treatment of hematologic malignancies. Informed consent was documented with the use of forms approved by the Institutional Review Board at the Fred Hutchinson Cancer Research Center. Patient characteristics are summarized in Table 1 . All grafts were G-CSF-mobilized peripheral blood mononuclear cells. A pathologist graded skin biopsies for GVHD in a blinded fashion, according to standard criteria (19) . Skin inflammation was also scored according to the degree of dermal infiltration and epidermal thickening and categorized as none (0); mild (1); moderate (2); or severe (3).
Combined immunofluorescence and FISH
Four millimeter punch biopsies of skin were fixed in 10% buffered formalin overnight and embedded in paraffin. Six micrometer sections were subjected to antigen retrieval using antigen unmasking solution (Vector Laboratories, Burlingame, CA). Dual FISH and immunofluorescence were performed as previously described (20) using the following antibodies and probes: Langerin Clone DCGM4 (Beckmann Coulter, Miamai, FL) with Cy2 anti-mouse IgG or biotinylated anti-mouse IgG and strepatividin Cy5 (Jackson Immunoresearch Inc., West Grove, PA); Ki-67 rabbit polyclonal (Vector Laboratories) with biotinylated anti-rabbit IgG, followed by streptavidin-Cy3 (Jackson Immunoresearch Inc.); SpectrumOrange X and SpectrumGreen Y chromosome enumeration probes (Vysis Inc., Des Plains, IL). FISH was performed before Langerin staining, except when Ki-67 was analyzed. In this case, Langerin and Ki-67 were stained before FISH and then Langerin was re-stained.
Leukocyte chimerism
CD11c + DCs, CD3 + T cells and CD33 + myeloid cells in peripheral blood, and CD11c + DCs from the bone marrow were sorted and subjected to VNTR-based chimerism analysis.
Statistical methods
Comparisons of chimerism values between groups were performed using a 2-sample Wilcoxon test. Comparisons of proportions of patients between groups defined by LCchimerism were performed using Chi-squared tests. Linear regression was used to evaluate correlation between skin GVHD stage, skin inflammation and LC-chimerism. A) The kinetics of donor Langerhans cells chimers after allogeneic HCT were assessed prospectively by combined XY-FISH and Langerin-immunohistochemistry as illustrated in Figure 1A and B. .02), conditioning intensity was not associated with statistically significant differences in levels of chimerism for these populations. F) Correlation between skin inflammation score and degree of donor Langerhans cell chimerism on day 28 after transplantation. The degree of skin inflammation was assessed as described in Patients and Methods and correlated with percentages of donor Langerhans cell chimerism (p=0.009). Data were derived from patients prepared with nonmyeloablative (black dots) or myeloablative (red dots) regimens. Table 1 Recipient and donor characteristics, GVHD and skin pathology of study subjects 
